Garrett M. Draper

Garrett M. Draper

Auto-generated profile, based on publicly available information

Garrett M. Draper

Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
BSBranden A. Smeester
Branden A. Smeester
GDGarrett M. Draper
Garrett M. Draper
NSNicholas J. Slipek
Nicholas J. Slipek
ALAlex T. Larsson
Alex T. Larsson
NSNatalie Stratton
Natalie Stratton
BMBranden S Moriarity
Branden S Moriarity
We previously identified ZNF217 as an oncogenic driver of a subset of osteosarcomas using the Sleeping Beauty (SB) transposon system. Here, we followed up by investigating the genetic role of ZNF217 in osteosarcoma initiation and progression through the establishment of a novel genetically engineered mouse model, in vitro assays, orthotopic mouse studies, and paired these findings with preclinical studies using a small-molecule inhibitor. Throughout, we demonstrate that ZNF217 is coupled to numerous facets of osteosarcoma transformation, including proliferation, cell motility, and anchorage independent growth, and ultimately promoting osteosarcoma growth, progression, and metastasis in part through positive modulation of PI3K–AKT survival signaling. Pharmacologic blockade of AKT signaling with nucleoside analogue triciribine in ZNF217+ orthotopically injected osteosarcoma cell lines reduced tumor growth and metastasis. Our data demonstrate that triciribine treatment may be a relevant and efficacious therapeutic strategy for patients with osteosarcoma with ZNF217+ and p-AKT rich tumors. With the recent revitalization of triciribine for clinical studies in other solid cancers, our study provides a rationale for further evaluation preclinically with the purpose of clinical evaluation in patients with incurable, ZNF217+ osteosarcoma.

1 October 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
KWKyle Williams
Kyle Williams
ALAlex T. Larsson
Alex T. Larsson
BKBryant J. Keller
Bryant J. Keller
KCKatherine E. Chaney
Katherine E. Chaney
RWRory L. Williams
Rory L. Williams
DLDavid Largaespada
David Largaespada
Neurofibromatosis type I (NF1) is a common cancer predisposition syndrome caused by heterozygous loss-of-function mutations in the tumor-suppressor gene NF1. Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell (SC) lineage after somatic loss of the wild-type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumors (MPNST). There is only one FDA-approved targeted therapy for symptomatic plexiform neurofibromas and none approved for MPNSTs. The genetic basis of NF1 syndrome makes associated tumors ideal for using synthetic drug sensitivity approaches to uncover therapeutic vulnerabilities. We developed a drug discovery pipeline to identify therapeutics for NF1-related tumors using isogeneic pairs of NF1-proficient and NF1-deficient immortalized human SCs. We utilized these in a large-scale high-throughput screen for drugs that preferentially kill NF1-deficient cells, through which we identified 23 compounds capable of killing NF1-deficient SCs with selectivity. Multiple hits from this screen clustered into classes defined by the method of action. Four clinically interesting drugs from these classes were tested in vivo using both a genetically engineered mouse model of high-grade PNSTs and human MPNST xenografts. All drugs tested showed single-agent efficacy in these models as well as significant synergy when used in combination with the MEK inhibitor selumetinib. This high-throughput screen platform yielded novel therapeutically relevant compounds for the treatment of NF1-associated tumors and can serve as a tool to rapidly evaluate new compounds and combinations in the future.

25 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KWKyle Williams
Kyle Williams
ALAlex T. Larsson
Alex T. Larsson
BKBryant J. Keller
Bryant J. Keller
KCKatherine E. Chaney
Katherine E. Chaney
RWRory L. Williams
Rory L. Williams
DLDavid Largaespada
David Largaespada
Neurofibromatosis Type 1 (NF1) is a common cancer predisposition syndrome, caused by heterozygous loss of function mutations in the tumor suppressor gene NF1 . Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage after somatic loss of the wild type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumors (MPNST). There is only one FDA approved targeted therapy for symptomatic plexiform neurofibromas and none approved for MPNST. The genetic basis of NF1 syndrome makes associated tumors ideal for using synthetic drug sensitivity approaches to uncover therapeutic vulnerabilities. We developed a drug discovery pipeline to identify therapeutics for NF1-related tumors using isogeneic pairs of NF1- proficient and deficient immortalized human Schwann cells. We utilized these in a large-scale high throughput screen (HTS) for drugs that preferentially kill NF1 -deficient cells, through which we identified 23 compounds capable of killing NF1- deficient Schwann cells with selectivity. Multiple hits from this screen clustered into classes defined by method of action. Four clinically interesting drugs from these classes were tested in vivo using both a genetically engineered mouse model of high-grade peripheral nerve sheath tumors and human MPNST xenografts. All drugs tested showed single agent efficacy in these models as well as significant synergy when used in combination with the MEK inhibitor Selumetinib. This HTS platform yielded novel therapeutically relevant compounds for the treatment of NF1-associated tumors and can serve as a tool to rapidly evaluate new compounds and combinations in the future.

19 April 2023 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
GDGarrett M. Draper
Garrett M. Draper
DPDaniel J. Panken
Daniel J. Panken
DLDavid Largaespada
David Largaespada
The advancement of CRISPR mediated gene engineering provides an opportunity to improve upon preclinical human cell line models of cancer predisposing syndromes. This review focuses on using CRISPR/Cas9 genome editing tools to model various human cancer predisposition syndromes. We examine the genetic mutations associated with neurofibromatosis type 1, Li-Fraumeni syndrome, Gorlin syndrome, BRCA mutant breast and ovarian cancers, and APC mutant cancers. Furthermore, we discuss the possibilities of using next-generation CRISPR-derived precision gene editing tools to introduce a variety of genetic lesions into human cell lines. The goal is to improve the quality of preclinical models surrounding these cancer predisposition syndromes through dissecting the effects of these mutations on the development of cancer and to provide new insights into the underlying mechanisms of these cancer predisposition syndromes. These studies demonstrate the continued utility and improvement of CRISPR/Cas9-induced human cell line models in studying the genetic basis of cancer.

3 April 2023
Verified
Other
Open access
BSBranden A. Smeester
Branden A. Smeester
GDGarrett M. Draper
Garrett M. Draper
NSNicholas J. Slipek
Nicholas J. Slipek
ALAlex T. Larsson
Alex T. Larsson
NSNatalie Stratton
Natalie Stratton
BMBranden S. Moriarity
Branden S. Moriarity
Supplementary data for Smeester et al.

3 April 2023
Verified
Other
Open access
BSBranden A. Smeester
Branden A. Smeester
GDGarrett M. Draper
Garrett M. Draper
NSNicholas J. Slipek
Nicholas J. Slipek
ALAlex T. Larsson
Alex T. Larsson
NSNatalie Stratton
Natalie Stratton
BMBranden S. Moriarity
Branden S. Moriarity
Antibodies and other reagents utilized